3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Ovarian Neoplasms
3
Breast Neoplasms
3
Neoplasms
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoadjuvant Therapy
1
Lung Neoplasms
1
Kenny-Caffey syndrome, Type 1
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
Oxaliplatin
18
Surveys and Questionnaires
15
Fluorouracil
15
Capecitabine
13
Leucovorin
12
Blood Specimen Collection
11
Irinotecan
10
Standard of Care
7
Cisplatin
7
Endoscopic Mucosal Resection
6
atezolizumab
5
Specimen Handling
5
Radiotherapy
5
Educational Status
5
Drug Therapy
5
Docetaxel
5
S 1 (combination)
4
Radiosurgery
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Interviews as Topic
4
Gemcitabine
4
Everolimus
4
Colonoscopy
4
Biopsy
4
Bevacizumab
4
tegafur-gimeracil-oteracil
3
pemigatinib
3
apatinib
3
Remote Patient Monitoring
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastrointestinal Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled